Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2012

View Archived Issues

Herbal flavonoid counteracts alcohol intoxication

Inverseon announces initial indication for INV-102

Researchers at Sanofi prepare novel endothelial lipase inhibitors

Sumagen set to start phase I testing of new HIV vaccine

Merck & Co. presents new GPR119 receptor agonists

Novel insulin-like growth factor 1 receptor antagonists patented by Novartis

Novel muscarinic acetylcholine M1 receptor positive allosteric modulators claimed

Abbott prepares new cannabinoid CB2 receptor ligands

U.S. team reports new method to stabilize proteins for therapeutic use

Boehringer Ingelheim and Vitae Pharmaceuticals patent new 11-beta-HSD1 inhibitors

MediciNova and University of Colorado Boulder collaborate on post-TBI therapy

Pergamum begins phase II DPK-060 trial in outer ear infections

Canadian study finds protein kinase inhibitors have potential to reverse resistance to antibiotics

Omni Bio plans new clinical studies of alpha-1-antitrypsin

DAPTA analogue reduces neuropathic pain in animal models

Vernalis and Servier establish new oncology collaboration

Additional funds support IDRI's work in tuberculosis

Evotec and Harvard University form new alliance

Xenetic Biosciences updates status of SymbioTec acquisition and SIIL arrangements

Idenix launches phase I/II IDX-719 study

Phase III study of elacytarabine delayed by manufacturing issues

LoneStar Heart acquires exclusive worldwide license

Ventana to develop companion diagnostic test for Bayer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...